Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Assessment of the sensitivity of DQF/ZQF 2H NMR of D2O for studying modified nafion membranes at 20 °C and 80 °C.

Thiessen AN, Verbeek W, Gritter K, Ooms KJ.

Solid State Nucl Magn Reson. 2018 Sep;93:1-6. doi: 10.1016/j.ssnmr.2018.03.005. Epub 2018 Apr 23.

PMID:
29758460
2.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

3.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.

Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24.

PMID:
27774990
4.

Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry.

Rubio-Tapia A, Malamut G, Verbeek WH, van Wanrooij RL, Leffler DA, Niveloni SI, Arguelles-Grande C, Lahr BD, Zinsmeister AR, Murray JA, Kelly CP, Bai JC, Green PH, Daum S, Mulder CJ, Cellier C.

Aliment Pharmacol Ther. 2016 Oct;44(7):704-14. doi: 10.1111/apt.13755. Epub 2016 Aug 3.

5.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S.

Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20. Epub 2016 Feb 9.

6.

GEP-NETs UPDATE: Secreting gastro-enteropancreatic neuroendocrine tumours and biomarkers.

Verbeek WH, Korse CM, Tesselaar ME.

Eur J Endocrinol. 2016 Jan;174(1):R1-7. doi: 10.1530/EJE-14-0971. Epub 2015 Jul 10. Review.

7.

JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, Manser AR, Uhrberg M, Verbeek W, Koschmieder S, Brümmendorf TH, Brossart P, Heine A, Wolf D.

Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1.

8.

A New and Validated Clinical Prognostic Model (EPI) for Enteropathy-Associated T-cell Lymphoma.

de Baaij LR, Berkhof J, van de Water JM, Sieniawski MK, Radersma M, Verbeek WH, Visser OJ, Oudejans JJ, Meijer CJ, Mulder CJ, Lennard AL, Cillessen SA.

Clin Cancer Res. 2015 Jul 1;21(13):3013-9. doi: 10.1158/1078-0432.CCR-14-2195. Epub 2015 Mar 16.

9.

[Diarrhoea and malabsorption due to olmesartan use].

van Beurden YH, Nijeboer P, Janssen J, Verbeek WH, Mulder CJ.

Ned Tijdschr Geneeskd. 2014;158:A7370. Dutch.

PMID:
24780574
10.

Evaluation of Cladribine treatment in refractory celiac disease type II.

Tack GJ, Verbeek WH, Al-Toma A, Kuik DJ, Schreurs MW, Visser O, Mulder CJ.

World J Gastroenterol. 2011 Jan 28;17(4):506-13. doi: 10.3748/wjg.v17.i4.506.

11.

Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy.

Tack GJ, Wondergem MJ, Al-Toma A, Verbeek WH, Schmittel A, Machado MV, Perri F, Ossenkoppele GJ, Huijgens PC, Schreurs MW, Mulder CJ, Visser OJ.

Bone Marrow Transplant. 2011 Jun;46(6):840-6. doi: 10.1038/bmt.2010.199. Epub 2010 Sep 6.

PMID:
20818442
12.

Accurate classification of RCD requires flow cytometry.

van Wanrooij RL, Schreurs MW, Bouma G, von Blomberg BM, Tack GJ, Verbeek WH, Mulder CJ.

Gut. 2010 Dec;59(12):1732. doi: 10.1136/gut.2010.223438. Epub 2010 Aug 30. No abstract available.

PMID:
20805314
13.

Phenotypic and genomic analysis of an exceptional case of enteropathy associated T-cell lymphoma.

Tack GJ, Verbeek WH, van de Water JM, von Blomberg BM, Bhola SL, Ylstra B, Mulder CJ, Schreurs MW.

Leuk Res. 2010 Aug;34(8):e183-9. doi: 10.1016/j.leukres.2010.02.018. Epub 2010 Mar 11. No abstract available.

PMID:
20226524
14.

The spectrum of celiac disease: epidemiology, clinical aspects and treatment.

Tack GJ, Verbeek WH, Schreurs MW, Mulder CJ.

Nat Rev Gastroenterol Hepatol. 2010 Apr;7(4):204-13. doi: 10.1038/nrgastro.2010.23. Epub 2010 Mar 9. Review.

PMID:
20212505
15.

Enteropathy associated T-cell lymphoma and its precursor lesions.

van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ.

Best Pract Res Clin Gastroenterol. 2010 Feb;24(1):43-56. doi: 10.1016/j.bpg.2009.11.002. Review.

PMID:
20206108
16.

Multiple common variants for celiac disease influencing immune gene expression.

Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, Zhernakova A, Heap GA, Adány R, Aromaa A, Bardella MT, van den Berg LH, Bockett NA, de la Concha EG, Dema B, Fehrmann RS, Fernández-Arquero M, Fiatal S, Grandone E, Green PM, Groen HJ, Gwilliam R, Houwen RH, Hunt SE, Kaukinen K, Kelleher D, Korponay-Szabo I, Kurppa K, MacMathuna P, Mäki M, Mazzilli MC, McCann OT, Mearin ML, Mein CA, Mirza MM, Mistry V, Mora B, Morley KI, Mulder CJ, Murray JA, Núñez C, Oosterom E, Ophoff RA, Polanco I, Peltonen L, Platteel M, Rybak A, Salomaa V, Schweizer JJ, Sperandeo MP, Tack GJ, Turner G, Veldink JH, Verbeek WH, Weersma RK, Wolters VM, Urcelay E, Cukrowska B, Greco L, Neuhausen SL, McManus R, Barisani D, Deloukas P, Barrett JC, Saavalainen P, Wijmenga C, van Heel DA.

Nat Genet. 2010 Apr;42(4):295-302. doi: 10.1038/ng.543. Epub 2010 Feb 28. Erratum in: Nat Genet.2010 May;42(5):465.

17.

Common and different genetic background for rheumatoid arthritis and coeliac disease.

Coenen MJ, Trynka G, Heskamp S, Franke B, van Diemen CC, Smolonska J, van Leeuwen M, Brouwer E, Boezen MH, Postma DS, Platteel M, Zanen P, Lammers JW, Groen HJ, Mali WP, Mulder CJ, Tack GJ, Verbeek WH, Wolters VM, Houwen RH, Mearin ML, van Heel DA, Radstake TR, van Riel PL, Wijmenga C, Barrera P, Zhernakova A.

Hum Mol Genet. 2009 Nov 1;18(21):4195-203. doi: 10.1093/hmg/ddp365. Epub 2009 Jul 31.

PMID:
19648290
18.

Aberrant T-lymphocytes in refractory coeliac disease are not strictly confined to a small intestinal intraepithelial localization.

Verbeek WH, von Blomberg BM, Coupe VM, Daum S, Mulder CJ, Schreurs MW.

Cytometry B Clin Cytom. 2009 Nov;76(6):367-74. doi: 10.1002/cyto.b.20481.

19.

Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling.

Trynka G, Zhernakova A, Romanos J, Franke L, Hunt KA, Turner G, Bruinenberg M, Heap GA, Platteel M, Ryan AW, de Kovel C, Holmes GK, Howdle PD, Walters JR, Sanders DS, Mulder CJ, Mearin ML, Verbeek WH, Trimble V, Stevens FM, Kelleher D, Barisani D, Bardella MT, McManus R, van Heel DA, Wijmenga C.

Gut. 2009 Aug;58(8):1078-83. doi: 10.1136/gut.2008.169052. Epub 2009 Feb 24.

PMID:
19240061
20.

The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease.

Verbeek WH, von Blomberg BM, Scholten PE, Kuik DJ, Mulder CJ, Schreurs MW.

Am J Gastroenterol. 2008 Dec;103(12):3152-8. doi: 10.1111/j.1572-0241.2008.02213.x.

PMID:
19086962
21.

Defective synthesis or association of T-cell receptor chains underlies loss of surface T-cell receptor-CD3 expression in enteropathy-associated T-cell lymphoma.

Tjon JM, Verbeek WH, Kooy-Winkelaar YM, Nguyen BH, van der Slik AR, Thompson A, Heemskerk MH, Schreurs MW, Dekking LH, Mulder CJ, van Bergen J, Koning F.

Blood. 2008 Dec 15;112(13):5103-10. doi: 10.1182/blood-2008-04-150748. Epub 2008 Sep 24.

22.

Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands.

Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CJ, Coupé VM.

Scand J Gastroenterol. 2008;43(11):1322-8. doi: 10.1080/00365520802240222.

PMID:
18618372
23.

[A changing spectrum: mucosal damage and the clinical picture of adult celiac disease].

Verbeek WH, Mulder CJ.

Gastroenterol Clin Biol. 2008 Mar;32(3):e3-4. doi: 10.1016/j.gcb.2008.03.008. Epub 2008 Apr 18. French. No abstract available.

24.

A changing spectrum: mucosal damage and the clinical picture of adult celiac disease.

Verbeek WH, Mulder CJ.

Gastroenterol Clin Biol. 2008 Mar;32(3):234-5. doi: 10.1016/j.gcb.2008.02.004. Epub 2008 Apr 11. No abstract available.

25.

Newly identified genetic risk variants for celiac disease related to the immune response.

Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D, Gwilliam R, Takeuchi F, McLaren WM, Holmes GK, Howdle PD, Walters JR, Sanders DS, Playford RJ, Trynka G, Mulder CJ, Mearin ML, Verbeek WH, Trimble V, Stevens FM, O'Morain C, Kennedy NP, Kelleher D, Pennington DJ, Strachan DP, McArdle WL, Mein CA, Wapenaar MC, Deloukas P, McGinnis R, McManus R, Wijmenga C, van Heel DA.

Nat Genet. 2008 Apr;40(4):395-402. doi: 10.1038/ng.102. Epub 2008 Mar 2.

26.

Novel approaches in the management of refractory celiac disease.

Verbeek WH, Schreurs MW, Visser OJ, von Blomberg BM, Al-Toma A, Mulder CJ.

Expert Rev Clin Immunol. 2008 Mar;4(2):205-19. doi: 10.1586/1744666X.4.2.205.

PMID:
20477051
27.

Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease.

Verbeek WH, Goerres MS, von Blomberg BM, Oudejans JJ, Scholten PE, Hadithi M, Al-Toma A, Schreurs MW, Mulder CJ.

Clin Immunol. 2008 Jan;126(1):48-56. Epub 2007 Nov 26.

PMID:
18024205
28.

Decreased circulating iNKT cell numbers in refractory coeliac disease.

Bernardo D, van Hoogstraten IM, Verbeek WH, Peña AS, Mearin ML, Arranz E, Garrote JA, Scheper RJ, Schreurs MW, Bontkes HJ, Mulder CJ, von Blomberg BM.

Clin Immunol. 2008 Feb;126(2):172-9. Epub 2007 Oct 31.

PMID:
17974485
29.

The MYO9B gene is a strong risk factor for developing refractory celiac disease.

Wolters VM, Verbeek WH, Zhernakova A, Onland-Moret C, Schreurs MW, Monsuur AJ, Verduijn W, Wijmenga C, Mulder CJ.

Clin Gastroenterol Hepatol. 2007 Dec;5(12):1399-405, 1405.e1-2. Epub 2007 Oct 29.

PMID:
17967566
30.

The management of complicated celiac disease.

Al-toma A, Verbeek WH, Mulder CJ.

Dig Dis. 2007;25(3):230-6.

31.

Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma.

Al-Toma A, Verbeek WH, Visser OJ, Kuijpers KC, Oudejans JJ, Kluin-Nelemans HC, Mulder CJ, Huijgens PC.

Dig Liver Dis. 2007 Jul;39(7):634-41. Epub 2007 May 24.

PMID:
17531561
32.

Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ.

Gut. 2007 Oct;56(10):1373-8. Epub 2007 Apr 30.

33.

Update on the management of refractory coeliac disease.

Al-Toma A, Verbeek WH, Mulder CJ.

J Gastrointestin Liver Dis. 2007 Mar;16(1):57-63. Review.

34.

DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.

Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W, Büchner T, Berdel WE, Serve H, Müller-Tidow C.

Cancer Res. 2007 Feb 1;67(3):1370-7.

35.

Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.

Al-toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huijgens PC, Mulder CJ.

Blood. 2007 Mar 1;109(5):2243-9. Epub 2006 Oct 26.

36.

Alemtuzumab for refractory celiac disease.

Verbeek WH, Mulder CJ, Zweegman S.

N Engl J Med. 2006 Sep 28;355(13):1396-7; author reply 1397. No abstract available.

37.

Catheter induced superior vena cava syndrome aggravated by shunt placement.

Verbeek WH, Riezebos RK, Siegert CE, Weijmer MC.

J Vasc Access. 2006 Apr-Jun;7(2):94-5.

PMID:
16868905
38.

Low-grade T-cell lymphoma of the kidney and Waldenström's macroglobulinemia in a patient presenting with renal failure.

Janssen U, Amann K, Reumel J, Boehm J, Verbeek W.

Clin Nephrol. 2006 Jun;65(6):441-5.

PMID:
16792141
39.
40.

[Which role do new therapeutic options play in palliative care of colorectal cancer?].

Verbeek W, Graeven U.

Internist (Berl). 2005 Dec;46(12):1339-46. Review. German.

PMID:
16228155
41.

Rectal adenocarcinoma with choriocarcinomatous differentiation: clinical and genetic aspects.

Verbeek W, Schulten HJ, Sperling M, Tiesmeier J, Stoop H, Dinjens W, Looijenga L, Wörmann B, Füzesi L, Donhuijsen K.

Hum Pathol. 2004 Nov;35(11):1427-30.

PMID:
15668903
42.

[Endoscopic removal of an intraluminal duodenal diverticulum in an adult with upper abdominal pain].

Heuer T, Frasch W, Gerards H, Verbeek W, Kohl D, Berkovic D, Reis HE.

Z Gastroenterol. 2004 Dec;42(12):1377-9. German.

PMID:
15592961
43.

Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy.

Tiesmeier J, Müller-Tidow C, Westermann A, Czwalinna A, Hoffmann M, Krauter J, Heil G, Ganser A, Serve H, Verbeek W.

Leuk Res. 2004 Oct;28(10):1069-74.

PMID:
15289019
44.

A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.

Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A.

Leukemia. 2004 Mar;18(3):460-5.

PMID:
14712285
45.

Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.

Tiesmeier J, Czwalinna A, Müller-Tidow C, Krauter J, Serve H, Heil G, Ganser A, Verbeek W.

Br J Haematol. 2003 Nov;123(3):413-9.

PMID:
14616999
46.

The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.

Kaeferstein A, Krug U, Tiesmeier J, Aivado M, Faulhaber M, Stadler M, Krauter J, Germing U, Hofmann WK, Koeffler HP, Ganser A, Verbeek W.

Leukemia. 2003 Feb;17(2):343-9.

PMID:
12592334
47.

In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF).

Faulhaber M, Wörmann B, Ganser A, Verbeek W.

Ann Hematol. 2002 Dec;81(12):695-700. Epub 2002 Nov 23.

PMID:
12483365
48.

Evolving treatment options of myelodysplastic syndromes.

Verbeek W, Ganser A.

Ann Hematol. 2001 Sep;80(9):499-509. Review.

PMID:
11669297
49.

DNase I hypersensitivity analysis of the human CCAAT enhancer binding protein epsilon (C/EBPepsilon) gene.

Kubota T, Hirama T, Verbeek W, Kawano S, Chih DY, Chumakov AM, Taguchi H, Koeffler HP.

Leuk Res. 2001 Nov;25(11):981-95.

PMID:
11597733
50.

C/EBPepsilon -/- mice: increased rate of myeloid proliferation and apoptosis.

Verbeek W, Wächter M, Lekstrom-Himes J, Koeffler HP.

Leukemia. 2001 Jan;15(1):103-11.

PMID:
11243377

Supplemental Content

Loading ...
Support Center